General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Janssen(SIGNIFICANT), Swedish Orphan Biovitrum(MODEST), Olatec(MODEST), Serpin Pharma(MODEST), Merck & Co., Inc.(MODEST), Astra Zeneca(MODEST), Implicit Biosciences(MODEST), Applied Clinical Intel(MODEST), Cromos Pharma(MODEST), Novo Nordisk Inc.(MODEST), Kiniksa(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Novartis(SIGNIFICANT), R-PHARM(SIGNIFICANT), Kiniksa(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Swedish Orphan Biovitrum(NONE)

View Full Disclosure